Skip to main content
. 2022 Apr 11;129:102827. doi: 10.1016/j.jaut.2022.102827

Fig. 3.

Fig. 3

Graphs depicting the IC50 values of vaccinated controls (green) and belimumab-treated patients after mRNA vaccination, stratified as high responders (in red) and low responders (in blue) *p < 0.05. IC50 corresponds to 50% inhibition of pseudovirus entry into the HEK293T-ACE2 cells at 7 days after exposure to non-diluted serum (101) or diluted serum (>101).